| Document Date: 2011-08-04 09:47:10
Open Document File Size: 145,04 KBShare Result on Facebook
City Wayne / / Company Bayer HealthCare Pharmaceuticals Inc. / Ames / Alteon Inc. / / Country Germany / United States / Canada / / Event Product Issues / FDA Phase / / IndustryTerm food / thyroid products / increased gas formation / chemical structure / / MedicalCondition partial intestinal obstruction / inflammatory bowel disease / postprandial hyperglycemia / liver dysfunction / chronic intestinal diseases / example rash / cirrhosis / thrombocytopenia / benign Leydig cell tumors / marked disorders / carbohydrate malnutrition / fulminant hepatitis / diabetic ketoacidosis / diarrhea / hypersensitivity / hepatitis / pneumatosis cystoides intestinalis / renal dysfunction / hypoglycemia / intestinal obstruction / abdominal pain / adenocarcinomas / adenomas / significant renal dysfunction / Carcinogenesis / hyperglycemia / ileus / erythema / fever / diabetes mellitus / exanthema / hypoglycemic shock / renal tumors / lactose intolerance / sometimes life-threatening hypoglycemia / Severe hypoglycemia / infection / / MedicalTreatment oral contraceptives / diabetic diet / diet therapy / surgery / insulin therapy / / Position PRECAUTIONS General / / Product ranitidine / glucagon / dextrose / nifedipine / isoniazid / PRECOSE / phenytoin / digoxin / glyburide / volunteers / acarbose / / ProvinceOrState New Jersey / / Technology alpha / DNA binding / pharmacokinetics / pharmacodynamics / /
SocialTag |
PRECOSE® is therapeutically desired. Following oral dosing of healthy volunteers with 14C-labeled acarbose, peak plasma concentrations of radioactivity were (acarbose tablets) attained 14–24 hours after dosing, while